Gene Panel Testing in Hereditary Breast Cancer.

BACKGROUND: Breast cancer (BC) is a highly complex, heterogeneous and multifactorial disease and is the most commonly diagnosed cancer and the leading cause of cancer-related mortality in women worldwide. Family history and genetic mutations are important risk factors for BC. While studies in twins have estimated that about 10%-30% of BC are due to hereditary factors, only 4%-5% of them are due to mutations in BRCA1 or BRCA2 genes. Our aim was to investigate the role of other BC genes in familial BC among the Iranian population. METHODS: We selected 61 BC patients who were wild-type for BRCA1 and BRCA2 mutations but who met the criteria for hereditary BC based on the American College of Medical Genetics and Genomics (ACMG) and the National Comprehensive Cancer Network (NCCN) guidelines. We performed targeted sequencing covering the exons of 130 known cancer susceptibility genes based on the Cancer Gene Census list. RESULTS: We found seven mutations in seven known BC susceptibility genes (RAD50, PTEN, TP53, POLH, DKC1, WRN and CHEK2) in seven patients including two pathogenic frameshift variants in RAD50 and WRN genes, four pathogenic missense variants in TP53, PTEN, POLH, and DKC1 genes and a pathogenic splice donor variant in the CHEK2 gene. The presence of all these variants was confirmed by Sanger sequencing and Gap reverse transcription-polymerase chain reaction (RT-PCR) for the splice variant. In silico analysis of all of these variants predicted them to be pathogenic. CONCLUSION: Panel testing of BC patients who met the established criteria for hereditary BC but who were negative for BRCA1/2 mutations provided additional relevant clinical information for approximately 11.5% of the families. Our findings indicate that next generation sequencing (NGS) is a powerful tool to investigative putative mutagenic variants among patients who meet the criteria for hereditary BC, but with negative results on BRCA1/2 testing.

Chromosomal aberrations in pregnancy and fetal loss: Insight on the effect of consanguinity, review of 1625 cases.

BACKGROUND: Pregnancy loss affects 10%-15% of pregnancies and is caused by several factors, maternal and fetal. Most common cause is chromosomal aneuploidy and has traditionally been detected by karyotyping product of conception and/or fetal tissue. In recent years, array comparative genomic hybridization (a-CGH) has been used because of its higher detection and lower failure rates. METHODS: DNA was extracted from 1625 products of abortion or fetal tissue. In 1,104 cases both quantitative fluorescent-polymerase chain reaction (QF-PCR) and a-CGH, and in 521 cases only a-CGH, was performed. RESULTS: The detection rate using QF-PCR and a-CGH is 20% compared to 12.7%, overall, and 15.7%, excluding failed samples, by karyotypes in our center. QF-PCR and a-CGH failed in 1.9% of cases, while the failure rate for karyotypes was 20.1%. The difference of detection and failure rates is significant (p-value < 0.001 and p-value < 0.001 respectively). Unexpectedly we also found a significant difference in frequency of imbalances in related versus unrelated couples. (χ2  = 11.4926, p-value < 0.001). CONCLUSION: It is highly likely that the pregnancy loss in consanguineous couples is caused by other genetic and immune mechanisms. It is plausible that, through the same mechanism by which single gene disorders have a higher prevalence of manifesting disease in consanguineous couples, they can cause lethal genetic disorders leading to pregnancy loss and intra-uterine fetal death (IUFD) in these couples. Our findings suggest that this is a matter for further study as it will greatly influence the approach to counseling and managing consanguineous couples with pregnancy loss.

Prenatal Screening for Aneuploidies Using QF-PCR and Karyotyping: A Comprehensive Study in Iranian Population.

BACKGROUND: We have investigated the efficacy of QF-PCR for the prenatal recognition of common aneuploidy and compared our findings with cytogenetic results in our laboratories. METHODS: A total of 4058 prenatal samples (4031 amniotic fluid and 27 chorionic villous samples) were analyzed by QF-PCR using several selected STR markers together with amelogenin. Results were compared to those obtained by conventional cytogenetic analysis. RESULTS: We detected 139 (3.42%) numerical abnormalities in our subjects by QF-PCR. Concordant QF-PCR and karyotype results were obtained in 4001 (98.59%) of the samples. An abnormal karyotype associated with adverse clinical outcome undetected by QF-PCR was found in 16.66% (n = 28) of samples. Using QF-PCR alone, we were able to detect abnormalities in 98.59% of all referred families; however the karyotyping results improved the detection rate to 99.85% of the referred cases. Individuals with neonatal screening result with 1:10 risk ratio showed 11.29% abnormal karyotype while this number was 2.16% in mothers with risk ratio of 1:250 or less. CONCLUSION: In countries where large scale conventional cytogenetic is hampered by its high cost and lack of technical expertise, QF-PCR may be used as the first line of screening for detection of chromosomal abnormalities. We also recommend QF-PCR for all the families that are seeking prenatal diagnosis of single gene disorders aneuploidies screening to be added to their work up.

Mutation profile of BBS genes in Iranian patients with Bardet-Biedl syndrome: genetic characterization and report of nine novel mutations in five BBS genes.

Bardet-Biedl syndrome (BBS) is a rare ciliopathy disorder that is clinically and genetically heterogeneous with 18 known genes. This study was performed to characterize responsible genes and mutation spectrum in a cohort of 14 Iranian families with BBS. Sanger sequencing of the most commonly mutated genes (BBS1, BBS2 and BBS10) accounting for ∼50% of BBS patients determined mutations only in BBS2, including three novel mutations. Next, three of the remaining patients were subjected to whole exome sequencing with 96% at 20 × depth of coverage that revealed novel BBS4 mutation. Observation of no mutation in the other patients represents the possible presence of novel genes. Screening of the remaining patients for six other genes (BBS3, BBS4, BBS6, BBS7, BBS9 and BBS12) revealed five novel mutations. This result represents another indication for the genetic heterogeneity of BBS and extends the mutational spectrum of the disease by introducing nine novel mutations in five BBS genes. In conclusion, although BBS1 and BBS10 are among the most commonly mutated genes in other populations like Caucasian, these two seem not to have an important role in Iranian patients. This suggests that a different strategy in molecular genetics diagnostic approaches in Middle Eastern countries such as Iran should be considered.

Involvement of the nucleus accumbens shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors.

BACKGROUND: Nucleus accumbens (NAc) and prefrontal cortex (PFC) dopaminergic and glutamatergic systems are involved in fear/anxiety-related behaviors; meanwhile NAc dopaminergic system activity is mediated by PFC via NAc glutamatergic projections. This study has investigated the involvement of NAc shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors. METHOD: Elevated plus-maze apparatus was employed to test parameters of anxiety-like behaviors in male Wistar rats. RESULTS: Unilateral intra-prelimbic injection of NMDA (0.9 µg/µl) but not D-AP7 (NMDA receptor antagonist; 0.25, 0.5 and 1 µg/µl) induced anxiolytic-like behaviors which was blocked by D-AP7. Moreover, unilateral infusion of SCH23390 (dopamine D1 receptor antagonist; 0.25, 0.5 and 1 µg/µl) and quinpirole (dopamine D2 receptor agonist; 0.125, 0.25 and 0.5 µg/µl) into the left NAc shell, did not alter anxiety-like behaviors. However, injection of SKF38393 (dopamine D1 receptor agonist; 3 µg/µl) and sulpiride (dopamine D2 receptor antagonist; 0.4 and 0.6 µg/µl) into the left NAc shell, likewise induced anxiolytic-like behaviors which were blocked by SCH23390 (0.25 µg/µl) and SKF96365 (Ca-channel blocker; 0.125 µg/µl)/SCH23390 (0.25 µg/µl), respectively. Furthermore, infusion of the subthreshold dose of SCH23390 (0.25 µg/µl) or quinpirole (0.25 µg/µl) into the left NAc shell, reduced while did not alter intra-prelimbic NMDA-induced anxiolytic-like behaviors, respectively. In addition, intra-NAc shell administration of the subthreshold dose of SKF38393 (1 µg/µl) or sulpiride (0.2 µg/µl), potentiated the lower dose response, while decreased the higher dose intra-left prelimbic NMDA response. CONCLUSION: Our results suggested a modulatory effect of the NAc shell dopaminergic system on prelimbic NMDA-induced anxiolytic-like behaviors.

Modulation of ventral tegmental area dopamine receptors inhibit nicotine-induced anxiogenic-like behavior in the central amygdala.

Nicotine, the major addictive substance in tobacco, increases the activity of the central amygdala (CeA). Amygdala is directly implicated in anxiety modulation and sends projections to the vicinity of the midbrain dopamine neurons, including the ventral tegmental area (VTA) which is a key area that controls nicotine dependence processes. In this study, the role of dopamine D(1) and D(2)/(3) receptors of the VTA on anxiogenic-like behavior induced with intra-CeA injection of nicotine has been investigated. Male Wistar rats with cannula aimed to the left CeA and the left VTA were submitted to the elevated plus-maze (EPM). The nicotine injection (1 µg/rat) into the CeA decreased the percentage of open arm time and open arm entries, but not locomotor activity, indicating an anxiogenic-like response. Intra-VTA injection of a dopamine D1 receptor antagonist, SCH23390 (0.25 µg/rat), and a dopamine D2/3 receptor antagonist, sulpiride (0.7 µg/rat), inhibited the anxiogenic-like response caused by intra-CeA injection of nicotine. These results suggest that the relationship between the VTA and the CeA may be involved in nicotine-induced anxiogenic-like behavior via dopamine D(1) and D(2)/(3) receptors. An understanding of these cellular processes will be crucial for the development of new intervention to combat nicotine effect.

The effect of cholestasis on rewarding and exploratory behaviors induced by opioidergic and dopaminergic agents in mice.

BACKGROUND: Several investigations have indicated that cholestasis decreases opioid receptor expression in the brain following increased opioidergic neurotransmission. The opioidergic system plays an important role in regulation of reward circuits that may be produced via dopamine-dependent mechanisms. It has been suggested that the dopaminergic system of the nucleus accumbens is necessary in conditioned place preference (CPP). The aim of this study is, therefore, to test if cholestasis can alter the reward system and the involvement of opioidergic and dopaminergic systems in this phenomenon.  METHODS: We used CPP and hole-board paradigms to measure the reward effect and exploratory behaviors, respectively, in mice. Cholestasis was induced by ligation of the main bile duct, using two ligatures and transecting the duct between them (BDL mice).  RESULTS: The data showed that morphine (1 and 2 mg/kg), sulpiride (80 mg/kg) and SKF38393 (20 mg/kg) produced CPP, while naloxone (1 mg/kg) and SCH23390 (1mg/kg) produced conditioned place aversion (CPA), whereas quinpirole had no effect in sham-operated mice. However, morphine (2 mg/kg, i.p.), sulpiride (40 mg/kg) and? SKF38393 (10 mg/kg) induced CPP in BDL mice compared to sham-operated mice. Naloxone- or SCH23390-induced CPA was reduced in BDL mice compared with the respective sham-operated mice. Quinpirole tended to induce aversion in BDL mice which was, however, not significant. In addition, quinpirole 1 mg/kg) and SCH23390 (1 mg/kg) increased head-dip exploratory behavior, whereas naloxone (2 mg/kg) caused a decrease in head-dip exploratory behavior in sham-operated mice. Morphine (2 mg/kg), SCH23390 (1 mg/kg) and quinpirole (0.25 and 0.5 mg/kg) induced anxiogenic-like behavior in BDL mice.  CONCLUSION: It can be concluded that cholestasis differentially alters the reward effects of opioidergic and dopaminergic agents.

Involvement of rat dopaminergic system of nucleus accumbens in nicotine-induced anxiogenic-like behaviors.

The objective of the present study was to investigate the involvement of dopamine D1 and D2 receptors of the nucleus accumbens (NAc) shell in the anxiogenic-like effect of intra-central amygdala (CeA) nicotine administration. Male Wistar rats with cannula implants in the left CeA and the left shell of NAc were submitted to the elevated plus-maze (EPM). Intra-CeA injections of nicotine (1 µg/rat) decreased % open arm time spent (%OAT) but not % open arm entries (%OAE) and locomotor activity, indicating the possibility of an anxiogenic-like response. Intra-NAc injection of D1 dopamine receptor antagonist, SCH23390 (0.5 µg/rat) but not other doses of the antagonist (0.06, 0.125 and 0.25 µg/rat) increased both %OAT and %OAE, showing an anxiolytic-like effect for the higher dose of the drug. Similar administration route of sulpiride (0.25, 0.5, 0.75 and 1 µg/rat), a selective antagonist at dopamine D2 receptor, had no significant effect on OAT%, OAE% and locomotor activity. Moreover, intra-CeA injection of nicotine (1 µg) with intra-NAc injection of sub-threshold doses of antagonists increased %OAT and %OAE without significant effect on locomotor activity. These findings may suggest the involvement of dopamine transmission, through D1 and D2 receptors of NAc shell, in the anxiogenic-like effect of nicotine in the EPM task.

Nicotine-induced anxiogenic-like behaviours of rats in the elevated plus-maze: possible role of NMDA receptors of the central amygdala.

The objective of the present study was to investigate the possible role of the N-methyl-D-aspartate (NMDA) receptor system of the central amygdala (CeA) in the anxiogenic-like effect of nicotine. Male Wistar rats with cannulas aimed to the CeA were submitted to the elevated plus-maze (EPM). Intraperitoneal (i.p.) injections of nicotine (0.6 and 0.8 mg/kg) decreased percentage open arm time spent (%OAT) and percentage open arm entries (%OAE), but not locomotor activity, indicating an anxiogenic-like response. Bilateral intra-CeA microinjection of NMDA (0.005-0.1 µ g/rat) decreased %OAT, but not %OAE and locomotor activity. Moreover, intra-CeA microinjection of NMDA (0.05 µ g) with an ineffective dose of nicotine (0.4 mg/kg, i.p.) reduced %OAT and %OAE without effect on locomotor activity. On the other hand, intra-CeA microinjection of the NMDA receptor antagonist D-AP5 (0.05-0.5 µ g/rat) increased both %OAT and %OAE, showing an anxiolytic-like effect of the drug. Co-administration of the same doses of D-AP5 with nicotine (0.6 mg/kg, i.p.) increased %OAT and %OAE, but not locomotor activity. Intra-CeA microinjection of D-AP5 reversed the response induced by NMDA (0.1 µ g/rat) in the EPM. The results may support the possible involvement of glutamate transmission, through NMDA receptors of central amygdala in the anxiogenic-like effect of nicotine in the EPM task.

GABAB receptors within the ventral tegmental area are involved in the expression and acquisition of morphine-induced place preference in morphine-sensitized rats.

The influence of intra-ventral tegmental area administration of gamma-amino-butyric-acid-B (GABAB) receptor agonist and antagonist on the expression and acquisition of morphine-induced conditioned place preference (CPP) in morphine-sensitized female rats was examined. Our pilot experiment showed that subcutaneous administration of morphine-(2.5, 5 and 7.5 mg/kg) induced CPP. Administration of one dose daily morphine (5 mg/kg) for 3 days followed by 5 days rest, enhanced the conditioning induced by ineffective doses of morphine (0.25, 0.5 and 1 mg/kg). Injections of GABAB receptor agonist, baclofen, (1.5 and 12 microg/rat) reduced the expression of morphine CPP whereas the dose of 6 microg/rat of the drug increased it. Baclofen also significantly reduced the acquisition of morphine CPP in morphine-sensitized animals. Administration of GABAB receptor antagonist, CGP 35348, significantly reduced the expression (12 microg/rat) and acquisition (1.5, 6 and 12 microg/rat) of morphine CPP in morphine-sensitized animals. In conclusion, results confirmed the importance of GABAB receptors within the ventral tegmental area of morphine CPP in morphine-sensitized female rats.

GABA and histamine interaction in the basolateral amygdala of rats in the plus-maze test of anxiety-like behaviors.

In the present study, we have investigated the effects and the interaction of the GABAergic and histaminergic systems in the basolateral amygdala (BLA) of rats using the plus-maze test of anxiety-like behaviors. Unilateral injection of different doses of muscimol (GABA(A) receptor selective agonist; 0.01, 0.05 and 0.1 microg/rat) into the BLA (intra-BLA) increased the percentage of open arm time (%OAT) and open arm entries (%OAE) at the doses of 0.05 and 0.1 microg/rat that are representative of an anxiolytic response. Intra-BLA injection of bicuculline (GABA(A) receptor selective antagonist; 0.05, 0.1 and 0.5 microg/rat) decreased %OAT and %OAE at the doses of 0.1 and 0.5 microg/rat showing an anxiogenic-like effect. Intra-BLA administration of histamine (0.05, 0.1 and 0.5 microg/rat) also showed anxiogenic-like effects at the doses of 0.1 and 0.5 microg/rat while intra-BLA administration of pyrilamine (an H1 receptor selective antagonist; 5, 10 and 20 microg/rat) induced anxiolytic effects at the dose of 20 microg/rat. Coadministration of histamine (0.1 microg/rat) with muscimol reversed the anxiolytic effect of muscimol at the dose of 0.1 microg/rat while coadministration of histamine (0.1 microg/rat) with bicuculline increased the anxiogenic effect of bicuculline at the dose of 0.05 microg/rat. On the other hand, coadministration of pyrilamine (10 microg/rat) with bicuculline decreased anxiety-like behaviors of bicuculline at the dose of 0.5 microg/rat while pyrilamine could not affect the anxiolytic effect of muscimol. In conclusion, it seems that both GABAergic and histaminergic systems not only play a part in the modulation of anxiety-like behaviors in the BLA of rats but may also have opposite effects in this brain region.

Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats.

The central histaminergic system is known to have modulatory influence on anxiety-related behaviour both in animals and humans through histamine H1 and/or H2 receptors. In the present study, the effects of intra-lateral septal microinjections of histaminergic agents on anxiety-related behaviours in male Wistar rats have been investigated. As a model of anxiety, the elevated plus-maze which is a useful test to investigate the effects of anxiogenic or anxiolytic drugs in rodents was used. Intra-lateral septal administration of histamine (0.5 and 1 microg/rat) decreased the percentage of open arm entries and open arm time but not locomotor activity, showing an anxiogenic response. The intra-lateral septal injections of different doses of the histamine H1 receptor antagonist, pyrilamine (5, 10 and 20 microg/rat) or the histamine H2 receptor antagonist, ranitidine (5, 10 and 20 microg/rat) could not significantly alter the anxiety-like parameters in the plus-maze test. However, intra-lateral septal injections of different doses of pyrilamine (10 and 20 microg/rat) or ranitidine (10 and 20 microg/rat) significantly reversed histamine (1 microg/rat)-induced anxiogenic effect. The results may indicate that the histaminergic system of lateral septum modulate anxiety-like behaviour through histamine H1 and H2 receptors.

Repeated pre-exposure to morphine into the ventral pallidum enhances morphine-induced place preference: involvement of dopaminergic and opioidergic mechanisms.

In the present study, the effect of repeated administration of morphine into the ventral pallidum (intra-VP) on the conditioned place preference (CPP) induced by systemic morphine injection was investigated in male Wistar rats. Subcutaneous (s.c.) administration of morphine (2.5, 5 and 7.5mg/kg), during conditioning, induced conditioned place preference (CPP). The maximum response was obtained with 5mg/kg of morphine. Lower dose of morphine (0.5mg/kg) did not induce CPP, but in the animals which had previously, received 3 days intra-VP repeated injections of morphine (3 or 5microg/rat) followed by 5 days free of the drug, elicited a significant CPP. Moreover, 3 days intraperitoneal (i.p.) pretreatment with different doses of naloxone (0.5, 1 and 2mg/kg), SCH 23390 (0.012, 0.025 and 0.05mg/kg) or sulpiride (6.2, 12.5 and 25mg/kg) in combination with repeated injections of morphine (5microg/rat), blocked the opioid response on the acquisition of morphine (0.5mg/kg) CPP. On the other hand, our results showed that 3 days single repeated administration of different doses of naloxone (0.5, 1 or 2mg/kg, i.p.), SCH 23390 but not sulpiride followed by 5 days free of the drug, significantly decreased the acquisition of morphine (0.5mg/kg) CPP and also induced place aversion. Furthermore, the drugs' injections had no effect on locomotor activity on the testing phase of CPP. It is concluded that repeated intra-VP injections of morphine induces behavioral sensitization, which may be due to the opioidrgic and/or dopaminergic mechanism(s).

The effects of histaminergic agents in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety.

High levels of histamine are found in the hippocampus. The central histamine system is involved in many physiological behavioural processes including anxiety-related behaviours both in animals and humans. In the present study, we investigated the effects of intra-hippocampal CA1 (intra-CA1) microinjection of histaminergic agents on anxiety-related behaviours in rats, using elevated plus-maze test of anxiety. Intra-CA1 administration of histamine (at the dose of 10 microg/rat) increased open arm time (%OAT) and open arm entry (%OAE) but not locomotor activity, thus showing an anxiolytic response. Intra-CA1 microinjection of pyrilamine (H1 receptor antagonist; at the doses of 10, 20 and 40 microg/rat) in combination with histamine (10 microg/rat) showed a decrease in the %OAT and %OAE. Higher dose of the antagonist (40 microg/rat) by itself increased both %OAT and %OAE, but not locomotor activity, indicating an anxiolytic effect. Intra-CA1 microinjection of ranitidine (H2 receptor antagonist), at the doses of 10, 20 and 40 microg/rat, also reduced the histamine response. Furthermore, the H2 receptor antagonist by itself reduced %OAT and %OAE without affecting locomotor activity. The results may indicate an anxiogenic effect for the antagonist. Our results showed that histamine may modulate anxiety via H1 and H2 receptors in the CA1 region of hippocampus of the rat.

Anxiolytic effect of noscapine in mice.

The anxiety-related effects of noscapine were investigated using male Balb-c mice. Since noscapine-induced locomotion may alter the animals' activity level in the dark-light model, the anxiety-related effects of noscapine were studied at doses with no effect on locomotion (0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1, 1.5 and 2 mg/kg). The parameter measured in dark-light model was the time spent in lit compartment. Intraperitoneal administration of noscapine (0.1-0.5 mg/kg) did not produce a significant effect on the time spent in the light, whereas higher doses (0.8, 1, 1.5 and 2 mg/kg) increased it significantly, implying an anxiolytic effect.

Histaminergic receptors of medial septum and conditioned place preference: D1 dopamine receptor mechanism.

In the present study, the effects of intra-medial septum injections of histamine and/or the histamine H1 or H2 receptor antagonists on the acquisition of conditioned place preference (CPP) in male Wistar rats have been investigated. Our data showed that the conditioning treatments with intra-medial septum injection of different doses of histamine (0.5-15 microg/rat) induced a significant CPP for the drug-associated place. Using a 3-day schedule of conditioning, it was found that the histamine H1 receptor antagonist, pyrilamine (10 and 15 microg/rat, intra-medial septum) also induced a significant place preference. In addition, pyrilamine inhibited the histamine (7.5 microg/rat)-induced place preference. Intra-medial septum administration of the histamine H2 receptor antagonist, ranitidine (5-15 microg/rat) alone or in combination with histamine did not produce a significant place preference or place aversion. On the other hand, intra-medial septum administration of the dopamine D1 receptor antagonist, SCH 233390 (0.5, 0.75 and 1 microg/rat) inhibited the histamine (7.5 microg/rat) or pyrilamine (15 microg/rat)-induced place preference in a dose-dependent manner, but no effect was observed for the dopamine D2 receptor antagonist, sulpiride on the histamine or pyrilamine response. The administration of histamine (2.5-15 microg/rat) or pyrilamine (10 and 15 microg/rat) during acquisition increased locomotor activity of the animals on the testing days. The results suggest that histaminergic receptors of the medial septum may be involved in CPP and thus it is postulated that dopamine D1 receptors may play an important role in this effect.

The effects of histaminergic agents in the ventral hippocampus of rats in the plus-maze test of anxiety-like behaviours.

It has been suggested that histamine have modulatory influence on anxiety-related behaviours both in animals and humans. Ventral hippocampus (VHC) may also be an important brain site in the modulation of fear or anxiety. In the present study, the effects of histaminergic agents on anxiety-related behaviours in the rats, using plus-maze test has been investigated. Intra-VHC administration of histamine (2.5, 5 and 7.5 microg/rat) decreased %OAT and %OAE but not locomotor activity, showing an anxiogenic response. Pretreatment of animals with either pyrilamine, a H1 receptor antagonist (10 microg/rat), or ranitidine, a H2 receptor antagonist (10 microg/rat) reverse anxiogenic response of histamine (2.5, 5 and 7.5 microg/rat). However, intra-VHC microinjection of higher doses of pyrilamine (40 microg/rat) or ranitidine (20 and 40 microg/rat) alone increased anxiety-like behaviours in rats. Our results showed that histamine may modulate anxiety-like behaviours via H1 and H2 receptors in the ventral hippocampus of the rats.

Repeated administration of dopaminergic agents in the nucleus accumbens and morphine-induced place preference.

In the present study, the effects of repeated intra nucleus accumbens (intra-NAc) injections of dopamine receptor agents on morphine-induced conditioned place preference (CPP) in rats were investigated by using an unbiased 3-days schedule of place conditioning design. The animals receiving once daily subcutaneous (s.c.) injections of morphine (0.5-7.5mg/kg) or saline (1.0 ml/kg, s.c.) showed a significant place preference in a dose-dependent manner. The maximum response was observed with 5mg/kg of the opioid. Three days intra-NAc injections of apomorphine (0.5 and 1 microg/rat) followed by 5 days free of the drug, increased or decreased, respectively CPP induced by the lower dose of morphine (0.5mg/kg, s.c.). Morphine-induced CPP was also significantly increased in the animals that had previously received the 3-days intra-NAc injections of SKF 38393 (4 and 8 microg/rat) or quinpirole (2 and 4 microg/rat, intra-NAc). The CPP induced by a higher dose of morphine (5mg/kg, s.c.) was significantly decreased in the animals that had previously received the 3-days SCH 23390 (0.005 and 0.01 microg/rat; intra-NAc). On the other hand, the CPP induced by morphine (5mg/kg, s.c.) was significantly increased in the animals that had previously received the 3-days sulpiride administration (5 microg/rat, intra-NAc). The 3-days administration of apomorphine, SKF 38393 or quinpirole, but not SCH 23390 and sulpiride reduced the locomotor activity in the test session. It is concluded that repeated injections of dopamine receptors agents followed by 5 days free of the drugs in the NAc can affect morphine reward.

The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice.

In the present study, effects of intracerebroventricular (i.c.v.) injections of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice were investigated by using a one-trial passive avoidance task. Amnesia induced by pre-training morphine was significantly reversed in morphine-sensitized mice, which had previously received once daily injections of morphine (20 and 30 mg/kg, s.c.) for 3 days. Three daily injections of SKF 38393 (1, 2 and 4 g/mouse, i.c.v.) or SCH 23390 (0.25, 0.5, 0.75 and 1 g/mouse, i.c.v.) before morphine, and during morphine-sensitization, decreased and increased the amnesia induced by pre-training morphine respectively. Three daily injections of quinpirole (0.3, 1 and 3 g/mouse, i.c.v.) or sulpiride (0.03, 0.1, 0.3 and 1 g/mouse, i.c.v.) before morphine, also decreased and increased the amnesia induced by pre-training morphine respectively. Morphine-sensitized mice received similar injections of cholinergic agents. Three daily injections of physostigmine (1, 3 and 5 g/mouse, i.c.v.) or atropine (1, 4 and 7 g/mouse, i.c.v.) before morphine, and during morphine-sensitization, decreased and increased the amnesia induced by pre-training morphine respectively. Three daily injections of nicotine (0.75, 1 and 2 g/mouse, i.c.v.) or mecamylamine (1, 3 and 6 g/mouse, i.c.v.) before morphine, also decreased and increased the amnesia induced by pre-training morphine respectively. The results suggest that morphine sensitization affects the impairment of memory formation and thus it is postulated that central dopaminergic and cholinergic systems may play an important role in this effect.

The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety.

Reports indicate that histamine and histaminergic agents can change anxiety-related behaviours in both animals and humans. The amygdala is an important brain site in the modulation of fear or anxiety. In the present study, we investigated the effects of intracentral amygdala microinjection of histaminergic agents on anxiety-related behaviours in rats, using the elevated plus-maze test of anxiety. Intracentral amygdala administration of histamine (0.01-0.5 microg/0.5 microl bilateral) decreased %open armtime and % open arm entries, but not locomotor activity, showing an anxiogenic response. Intracentral amygdala microinjection of pyrilamine (H1 receptor antagonist) and ranitidine (H2 receptor antagonist) (both at 1-20 microg/0.5 microl bilateral) did not change anxiety-related parameters in our experiments. In another series of experiments, histamine (0.5 microg/0.5 microl bilateral) was coadministrated with pyrilamine and ranitidine (both at 1-20 mg/0.5 microl bilateral). The results showed that pyrilamine but not ranitidine could significantly reverse the anxiogenic effect of histamine at doses of 10 and 20 microg/0.5 microl bilateral. The results suggest that histamine may modulate anxiety via H1 but not H2 receptors in the rat central amygdala.